This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month.  This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month.  Do not discuss goals or future plans unless they have crystallized to the point that they are “material information” as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

• Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered, nor should questions be omitted or left unanswered.  The answers to the items must be in narrative form.  State when the answer to any item is negative or not applicable to the Issuer.  The title to each item must precede the answer.
• The term “Issuer” includes the Issuer and any of its subsidiaries.
• Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer continued its business of developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor, and assess treatment for cancer early, accurately and cost effectively.

2. Provide a general overview and discussion of the activities of management.

• The pandemic has entered the endemic stage with restrictions being relaxed globally. There are still concerns of higher infection rates due to the Omricon BA.4 and BA.5 subvariants that are becoming dominant strains with high transmission rates. 4 and BA.5 now account for more than 21% of new cases in the U.S., according to U.S. Centers for Disease Control and Prevention (CDC) estimatesas of June 11, 2022. These two new subvariants evolved from the Omicron lineage to become even more contagious and can bypass immunity from a past infection or vaccination, experts say. This means people can be reinfected even if they had Omicron earlier this year. Health care focus is on the fall where there are concerns of a spike in cases due to the annual flu virus. Financial, operational and recovery measures instituted by the management team aided in sustaining business viability over the past 24 months and the company intends to navigate through the endemic phase diligently.
• On June 7, 2022, BioMark announced that BioMark and the Icahn School of Medicine at Mount Sinai in New York (“Icahn Mount Sinai”) entered into collaborative research agreement to work together on clinical studies related to early lung cancer diagnosis for at risk population using a set of proprietary plasma biomarkers and machine learning algorithms discovered and developed by BioMark. This initiative is part of BioMark’s effort to commercialize its liquid-biopsy technology that leverages the latest advances in metabolomics and machine learning algorithms in the US. The test developed through this dynamic collaboration would offer the opportunity to screen nearly 16 million individuals eligible for lung cancer screening under current US guidelines could be significantly improved with a widely accessible blood-based cancer screening.
• BioMark and Phytronix presented a poster at the ASMS held in Minneapolis from June 5-9, 2022. Abstract title:“Quantification of Beta-Hydroxybutyric acid and Tryptophan in plasma as metabolic biomarkers of cancer using the LDTD-MS/MS technique”. The poster attracted interest from many potential companies in the clinical lab space on the use of this novel integrated technology for cancer screening application.
• BioMark attended the BIO International Convention 2022, held in June 13-16, 2022, in San Diego, CA. The Company presented in several one-on-one meetings with potential investors, strategic biopharma and lab collaborators/partners. Quebec government and Mitacs partially sponsored BioMark’s participation and provided access to its booth at the Canadian pavilion. The meetings with specific states and institutions across United States are being followed upon as these avenues will be critical as BioMark expands its operational footprint into US and other global jurisdictions that have expressed interest in the company’s early lung cancer blood-based assay.
• On June 21^st, 2022, BioMark announced that it has obtained a novel patent in Japan, No.7038044, further strengthening the Company’s intellectual property position worldwide and coverage of its blood-based technology for early lung cancer detection and screening. The Japan Patent Office is the first to issue patent on the Company’s biomarker panel for detecting lung cancer, which belongs to a large family of patents that BioMark owns, and complements similar patents currently pending in Canada, China, Europe, and US. In addition, BioMark successfully obtained certificate of registration for BioMark trademark use in Canada under Ref.: Canada R#021131-0028. The issued trademark will be used in Canada in association with the wares and/or services described in the registration which is what the company is planning to introduce firstly on its lung cancer screening assay primed for commercialization early next year.
• On June 30, 2022, BioMark Diagnostic Solution signed the Letter of Intent with TransDiag in France. TransDiag has been successful in attracting well-known clinical institutions and collaborators to partner with BioMark to conduct trials that will be useful in assessing, reviewing, and establishing a lung cancer screening platform in Europe, starting in France. The parties are looking to commence the trials on a screening program for early lung cancer in September 2022. The 2 groups are jointly reviewing international research sponsored programs offered by the Federal government from both counties that encourages collaboration and innovation.
• BioMark’s business development advisor for Europe and Middle East is exploring potential partnerships in Qatar with various medical institutions and Health Ministry on setting up clinical collaborations and technology development capacity related to early diagnosis and prevention solutions. Presentations were made to senior government officials and special meetings are scheduled for later in July and August of 2022.
• BioMark continued to entertain discussions with various financial institutions and government agencies to secure non-dilutive funding, favourable loans and equity investments to accelerate the commercialization of its early lung cancer liquid biopsy franchise and to advance its expansion strategy in Quebec and the USA and for general corporate purposes. Exploratory meetings were scheduled at Bio 2022 in June with government agencies from Texas, Maryland and other NIH and NCI funded cancer facilities.  
• BioMark Diagnostics Solutions Inc. submitted an application to join the Medical Alley Association’s US Market Access Acceleration Program to help have a deeper understanding of biotech sector in the US and build contacts. Decision is expected in mid-July that will announce the successful applicants.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Not applicable.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Not applicable.

5. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Not applicable.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Not applicable.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Not applicable.

8. Describe the acquisition of new customers or loss of customers.

Not applicable.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

BioMark obtained a novel patent in Japan, No.7038044, further strengthening the Company’s intellectual property position worldwide and coverage of its blood-based technology for early lung cancer detection and screening. In addition, BioMark received the certificate of registration for BioMark trademark use in Canada under Ref.: Canada R#021131-0028. The issued trademark will be used in Canada in association with the wares and/or services described in the registration.

The Issuer continues to file trademark and patents in specific jurisdictions for all its patents. Review of the filings and opinions from patent offices are being reviewed as needed.

10. Report on any employee hiring, terminations or lay-offs with details of anticipated length of lay-offs.

Not applicable.

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not applicable.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Not applicable.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Not applicable.

14. Provide details of any securities issued and options or warrants granted.

On June 14^th, 2022, 250,000 shares have been issued upon the exercise of the options at a price of $0.15 per share for gross proceeds of $ 37,500.

15. Provide details of any loans to or by Related Persons.

Not applicable.

16. Provide details of any changes in directors, officers, or committee members.

Not applicable.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.

The trends and risks which are likely to impact the Issuer are discussed in the Form 51-102F1 Management’s Discussion & Analysis Annual Report for the Year Ended March 31, 2021.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there where is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.